The discovery by researchers at Linkoping University in Sweden helps to explain why infection with HIV greatly increases the risk that infection by tuberculosis bacterium (Mtb) will progress to active tuberculosis.
In most people who are exposed to tuberculosis infection, the immune defence deals with the bacteria by enclosing them in a special scar tissue. In this condition the tuberculosis is said to be "latent".
Around 10 per cent of those with latent tuberculosis will go on to develop active disease. We know that infection with HIV is the greatest risk factor for the development of active tuberculosis after infection with Mtb.
In the new study, the researchers looked in more detail at what happens in one particular type of immune cell, known as dendritic cells.
These play an important role in the immune defence. Dendritic cells break down tuberculosis bacteria and other foreign microorganisms, and display the bacteria fragments at the cell surface.
Other cells of the immune system, in particular T-cells, recognise the fragments and bind to them. The dendritic cell then activates the T-cell such that it can kill the tuberculosis bacteria efficiently.
The researchers infected human dendritic cells with both Mtb and the HIV virus. They showed that co-infection reduced the ability of the dendritic cells to present foreign molecules to the immune defence.
They also had a lower capacity to activate tuberculosis-specific T-cells than was the case when the dendritic cells were infected with Mtb alone.
"We have now shown that HIV has a clear effect also on the innate immune defence, in particular the dendritic cells, which link the innate and the adaptive immune defences.
According to the World Health Organisation (WHO), around 9.6 million people around the world develop tuberculosis each year, researchers said.
About 10 per cent of these, or 1.2 million people, are also infected with HIV. Of those who die from tuberculosis, one third are infected by HIV, but the fraction differs greatly between different parts of the world.
The study was published in the American Journal of Pathology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
